Differential changes in serum uric acid concentrations in sibutramine promoted weight loss in diabetes: Results from four weeks of the lead-in period of the SCOUT trial

Nutrition and Metabolism

Volumn 6, Issue 1, 2009, Pages

  Andersson, Charlotte ^a   Weeke, Peter ^a   Brendorp, Bente ^b   Køber, Lars ^c   Fosbøl, Emil L ^a   Sharma, Arya M ^d   Finer, Nick ^e   Caterson, Ian D ^f   Rode, Richard A ^g   James, Philip T ^h   Torp Pedersen, Christian ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^c Rigshospitalet   (Denmark)

^d UNIVERSITY OF ALBERTA   (Canada)

^e ADDENBROOKE S HOSPITAL   (United Kingdom)

^f UNIVERSITY OF SYDNEY   (Australia)

^g ABBOTT LABORATORIES   (United States)

^h LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84929470443     PISSN: None     EISSN: 17437075     Source Type: Journal    
DOI: 10.1186/1743-7075-6-42     Document Type: Article

References (28)

1. Fang J, Alderman MH: Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. Jama 2000, 283:2404-10.
2. Strasak A, Ruttmann E, Brant L, et al.: Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83,683 Austrian men. Clin Chem 2008, 54:273-84.
3. Strasak AM, Kelleher CC, Brant LJ, et al.: Serum uric acid is an independent predictor for all major forms of cardiovascular death in 28,613 elderly women: a prospective 21-year follow-up study. Int J Cardiol 2008, 125:232-9.
4. Niskanen LK, Laaksonen DE, Nyyssonen K, et al.: Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 2004, 164:1546-51.
5. Feig DI, Kang DH, Johnson RJ: Uric acid and cardiovascular risk. N Engl J Med 2008, 359:1811-21.
6. Ebrahimpour P, Fakhrzadeh H, Heshmat R, et al.: Serum uric acid levels and risk of metabolic syndrome in healthy adults. Endocr Pract 2008, 14:298-304.
7. Ford ES, Li C, Cook S, et al.: Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation 2007, 115:2526-32.
8. Filippatos TD, Kiortsis DN, Liberopoulos EN, et al.: A review of the metabolic effects of sibutramine. Curr Med Res Opin 2005, 21:457-68.
9. Torp-Pedersen C, Caterson I, Coutinho W, et al.: Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J 2007, 28:2915-23.
10. Levey AS, Bosch JP, Lewis JB, et al.: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130:461-70.
11. Andersson C, Weeke P, Fosbol EL, et al.: Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial. Metabolism 2009, 58:1109-15.
12. Tsouli SG, Liberopoulos EN, Mikhailidis DP, et al.: Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism 2006, 55:1293-301.
13. Apfelbaum M, Vague P, Ziegler O, et al.: Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999, 106:179-84.
14. Bray GA, Blackburn GL, Ferguson JM, et al.: Sibutramine produces dose-related weight loss. Obes Res 1999, 7:189-98.
15. Smith IG, Goulder MA: Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract 2001, 50:505-12.
16. Marangella M: Uric acid elimination in the urine. Pathophysiological implications. Contrib Nephrol 2005, 147:132-48.
17. Anzai N, Kanai Y, Endou H: New insights into renal transport of urate. Curr Opin Rheumatol 2007, 19:151-7.
18. Anzai N, Ichida K, Jutabha P, et al. : Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. J Biol Chem 2008, 283:26834-8.
19. Caulfield MJ, Munroe PB, O'Neill D, et al.: SLC2A9 is a high-capacity urate transporter in humans. PLoS Med 2008, 5:e197.
20. Augustin R, Carayannopoulos MO, Dowd LO, et al.: Identification and characterization of human glucose transporter-like protein-9 (GLUT9): alternative splicing alters trafficking. J Biol Chem 2004, 279:16229-36.
21. Nan H, Dong Y, Gao W, et al.: Diabetes associated with a low serum uric acid level in a general Chinese population. Diabetes Res Clin Pract 2007, 76:68-74.
22. Facchini F, Chen YD, Hollenbeck CB, et al.: Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. Jama 1991, 266:3008-11.
23. Quinones Galvan A, Natali A, Baldi S, et al.: Effect of insulin on uric acid excretion in humans. Am J Physiol 1995, 268:E1-5.
24. Ter Maaten JC, Voorburg A, Heine RJ, et al.: Renal handling of urate and sodium during acute physiological hyperinsulinaemia in healthy subjects. Clin Sci (Lond) 1997, 92:51-8.
25. Kerndt PR, Naughton JL, Driscoll CE, et al.: Fasting: the history, pathophysiology and complications. West J Med 1982, 137:379-99.
26. Feher MD, Hepburn AL, Hogarth MB, et al.: Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. Rheumatology (Oxford) 2003, 42:321-5.
27. Ka T, Inokuchi T, Tsutsumi Z, et al.: Effects of a fenofibrate/losartan combination on the plasma concentration and urinary excretion of purine bases. Int J Clin Pharmacol Ther 2006, 44: 22-6.
28. Lee YH, Lee CH, Lee J: Effect of fenofibrate in combination with urate lowering agents in patients with gout. Korean J Intern Med 2006, 21:89-93.